Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes.

A study published in the journal Diabetes, Obesity & Metabolism explores the effects of the drug empagliflozin on metabolic dysfunction-associated steatotic liver disease (MASLD) in a mouse model of lipoatrophic diabetes. The researchers found that empagliflozin prevented the development of MASLD in mice and reduced liver steatosis in older mice. The drug achieved these effects by reducing de novo lipogenesis, the process by which the liver produces new fat. The study suggests that empagliflozin could be a potential therapeutic option for managing MASLD associated with lipodystrophies. [Extracted from the article]